Squarepoint Ops LLC Has $4.58 Million Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Squarepoint Ops LLC lifted its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 12.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,125 shares of the company’s stock after acquiring an additional 14,799 shares during the period. Squarepoint Ops LLC owned approximately 0.33% of RxSight worth $4,577,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Private Trust Co. NA bought a new stake in shares of RxSight during the fourth quarter worth $34,000. State of Wyoming bought a new stake in shares of RxSight during the fourth quarter worth $37,000. Coppell Advisory Solutions LLC increased its position in shares of RxSight by 108.9% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company’s stock worth $44,000 after acquiring an additional 672 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in shares of RxSight during the fourth quarter worth $46,000. Finally, Global Retirement Partners LLC bought a new stake in shares of RxSight during the fourth quarter worth $69,000. Institutional investors own 78.78% of the company’s stock.

RxSight Price Performance

Shares of RXST stock opened at $15.68 on Monday. The stock has a market cap of $637.19 million, a P/E ratio of -18.89 and a beta of 1.32. The company has a fifty day moving average price of $17.11 and a two-hundred day moving average price of $28.70. RxSight, Inc. has a one year low of $12.53 and a one year high of $62.50.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The firm had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $38.74 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.25) earnings per share. As a group, equities research analysts anticipate that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on RXST shares. Wells Fargo & Company raised shares of RxSight from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $17.00 to $25.00 in a research report on Monday, May 19th. UBS Group downgraded shares of RxSight from a “buy” rating to a “neutral” rating and decreased their target price for the company from $45.00 to $16.00 in a research report on Wednesday, April 9th. Piper Sandler assumed coverage on shares of RxSight in a research report on Tuesday, April 15th. They issued a “neutral” rating and a $18.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 target price on shares of RxSight in a research report on Thursday, April 3rd. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $17.00 target price (down previously from $40.00) on shares of RxSight in a research report on Friday, April 4th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $37.90.

Insider Buying and Selling at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares in the company, valued at approximately $637,428.03. This trade represents a 22.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 9.36% of the company’s stock.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.